Atazanavir-d6 [CAS 1092540-50-5]

Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) [2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

[1092540-50-5]

C38H46D6N6O7

710.89

[2H]C([2H])([2H])OC(N[C@@H](C(C)(C)C)C(N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(NC([C@H](C(C)(C)C)NC(OC([2H])([2H])[2H])=O)=O)CC2=CC=C(C3=CC=CC=N3)C=C2)=O)=O

Cytochrome P450; Endogenous Metabolite; HIV; HIV Protease; Isotope-Labeled Compounds; P-glycoprotein; SARS-CoV

99.28

10 mM in DMSO

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature

H302-H315-H319-H335

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501